International Journal of Cancer Management

Published by: Kowsar

Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study

Asiie Olfatbakhsh 1 , * , Hoda Tafazzoli-Harandi 1 , Safa Najafi 1 , Esmat Al Sadat Hashemi 1 , Fateme Sari 1 , Parisa Mokhtari Hesari 2 and Parisa Hosseinpour 1
Authors Information
1 Breast Disease Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, IR Iran
2 Integrative Medicine Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, IR Iran
Article information
  • International Journal of Cancer Management: May 2018, 11 (5); e60098
  • Published Online: May 12, 2018
  • Article Type: Research Article
  • Received: November 28, 2017
  • Revised: February 4, 2018
  • Accepted: February 19, 2018
  • DOI: 10.5812/ijcm.60098

To Cite: Olfatbakhsh A, Tafazzoli-Harandi H, Najafi S, Hashemi E A S, Sari F, et al. Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study, Int J Cancer Manag. 2018 ; 11(5):e60098. doi: 10.5812/ijcm.60098.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188-94. doi: 10.1093/jnci/dji021. [PubMed: 15687361].
  • 2. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24(7):1037-44. doi: 10.1200/JCO.2005.02.6914. [PubMed: 16505422].
  • 3. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650-5. doi: 10.1200/JCO.2006.08.2271. [PubMed: 17602071].
  • 4. Chollet P, Amat S, Cure H. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86(7):1041-6.
  • 5. Bolan PJ, Wey A, Eberly L. Assessing prognosis and therapy response in primary systemic therapy of breast cancer with magnetic resonance spectroscopy. Cancer Res. 2012;72(24):1-14.
  • 6. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011;9(4):199-207. doi: 10.1038/nrclinonc.2011.165. [PubMed: 22064459].
  • 7. Cortazar P, Zhang L, Untch M. Abstract S1-11: meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Res. 2012;72(24):1-11. doi: 10.1038/sj/bjc/6600210.
  • 8. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med. 2009;50 Suppl 1:55S-63S. doi: 10.2967/jnumed.108.057240. [PubMed: 19380410].
  • 9. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91(12):2012-7. doi: 10.1038/sj.bjc.6602235. [PubMed: 15558072]. [PubMed Central: PMC2409783].
  • 10. Andrade DA, Zucca-Matthes G, Vieira RA, Andrade CT, Costa AM, Monteiro AJ, et al. Neoadjuvant chemotherapy and pathologic response: a retrospective cohort. Einstein (Sao Paulo). 2013;11(4):446-50. [PubMed: 24488382]. [PubMed Central: PMC4880380].
  • 11. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342-54. doi: 10.1016/j.ejca.2012.05.023. [PubMed: 22766518].
  • 12. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-74. doi: 10.1200/JCO.2003.12.005. [PubMed: 14559892].
  • 13. Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19(23):6360-70. doi: 10.1158/1078-0432.CCR-13-0916. [PubMed: 24298066].
  • 14. Miglietta L, Venella P, Canobbio L, Parodi MA, Guglielmini P, Buccardo P. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. Anticancer Res. 2009;29(5):1621-5.
  • 15. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. [PubMed: 22508812].
  • 16. Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast. 2009;18 Suppl 3:S137-40. doi: 10.1016/S0960-9776(09)70289-9. [PubMed: 19914533].
  • 17. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40(2):205-11. [PubMed: 14728934].
  • 18. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486. doi: 10.1186/1471-2407-11-486. [PubMed: 22081974]. [PubMed Central: PMC3262864].
  • 19. Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O'Regan R, et al. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Am J Clin Pathol. 2016;145(6):871-8. doi: 10.1093/ajcp/aqw045. [PubMed: 27298399].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments